Summarized by Masters of Longevity from Longevity Technology.
Zervimesine coverage preview: a news article on a newly patented crystalline form and the company's next regulatory and manufacturing steps.
Key Takeaways
- A newly issued US patent protects a specific crystalline polymorph of zervimesine, extending proprietary composition and manufacturing claims through 2045.
- Zervimesine (CT1812) is an investigational once-daily oral neurotherapy that showed promise in Phase 2 trials for dementia with Lewy bodies and mild-to-moderate Alzheimer’s disease.
- Cognition Therapeutics plans to finalize registrational endpoints with the FDA and begin manufacturing the new crystalline form in early 2027 if regulatory feedback is favorable.
